PPBT - Purple Biotech

Momentum: Bearish

Recent News

Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire • 2 weeks, 5 days ago • score: 0.14

REHOVOT, Israel, Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- Purple Biotech Ltd. ( "Purple Biotech" or "the Company" ) ( NASDAQ/TASE: PPBT ) , a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that the Company's ...

Neutral

Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform - Purple Biotech ( NASDAQ:PPBT )

Benzinga • 3 months, 1 week ago • score: 0.13

REHOVOT, Israel, June 04, 2025 ( GLOBE NEWSWIRE ) -- Purple Biotech Ltd. ( "Purple Biotech" or "the Company" ) ( NASDAQ/TASE: PPBT ) , a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced a poster ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United States. The company is headquartered in Rehovot, Israel.

52W High

$9.40

52W Low

$0.60

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-0.51

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.15

EV/Revenue (<3 favorable)

33.08

P/S (TTM) (<3 favorable)

58.08

P/B (<3 favorable)

0.06

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

0.00%

Institutions (25–75% balanced)

1.89%

Shares Outstanding

3,030,400

Float

541,350,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

-62,000

EPS (TTM)

-45.90

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.09%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.5731

-0.5682

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025